Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.
Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]
Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.
Teenagers and young adults living with perinatally acquired HIV (PaHIV) have a higher risk of developing malignancies and a higher all-cause mortality rate than their non-HIV-infected peers, according to a study from the UK.
Chemotherapy may be less damaging to fertility of female lymphoma patients who are of a younger age than those who are older, even in the case of an alkylating regimen, suggests a study presented at ESHRE 2018.
Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.
In the first-line treatment of patients with advanced-stage Hodgkin’s lymphoma, a modified regimen containing the antibody-drug conjugate brentuximab vedotin prolongs progression-free survival and reduces the risk of primary chemotherapy failure at 2 years when compared with a standard four-drug regimen containing bleomycin, according to the results of the phase III ECHELON-1 trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.